Extended comment period for IVDMIA guidance
This article was originally published in The Gray Sheet
Executive Summary
Stakeholders have until Oct. 17 to submit additional comments on FDA's draft guidance on in vitro diagnostic multivariate index assays. A 30-day comment period on the agency's revised draft, which would assert FDA enforcement over certain lab-developed tests, initially closed Aug. 27, but critics said there had been insufficient time to thoroughly evaluate the guidance's implications (1"The Gray Sheet" Sept. 3, 2007, p. 7)
You may also be interested in...
Lab Stakeholders Still Oppose FDA’s Multivariate Assay Policy
Laboratories are urging FDA to once again rework, if not abandon, its proposal to actively regulate certain lab-developed tests, while diagnostics companies are split on the issue
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.